What is RPRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 32.53B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RPRX?

P/E (TTM) is 39.89 and 52-week range is $35.23 to $64.38 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RPRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RPRX?

The company profile lists revenue (TTM) near $2.62B, net income (TTM) near $843M, EPS (TTM) near $1.46 when available from the market-data feed. Figures are informational and may lag live markets.

Does RPRX show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $0.69, yield near 1.23%, ex-dividend date Aug 14, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Royalty Pharma PLC based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 575.8M shares outstanding, ISIN GB00BMVP7Y09 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Royalty Pharma PLC

$RPRX

Health Care · Pharmaceuticals

IR Run Scenarios

$56.57

-2.09%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 100 full-time employees. The company went IPO on 2020-06-16. The company collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.

Employees

100

Website

www.royaltypharma.com/

IPO

2020-06-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)